More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Zandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.

Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.

Posaconazole-loaded liposomes decorated with penetratin show up to 1300 times increased efficacy against biofilm formation and reduce fungal burden by 60% in murine models.

Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases discusses the results of the organization's new survey and the surprising findings that many people forget to wash their hands after key times or believe it is not needed.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

A small percentage of people who contract the tick-borne illness have lingering symptoms and health issues after the acute infection has been treated, but there are no FDA-approved therapies to deal with prolonged symptoms. A new report looks to address this issue.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Pertussis, also known as whooping cough, saw more cases last year than in the last decade, and it is on track for another record year for cases. Sharon Nachman, MD, provides clinical insights for presentation, treatment, and vaccination.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

A large retrospective cohort study demonstrates greater resistance across different pathogens in this patient population compared with those who do not have cancer.

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit

Paul Offit, MD, offers a glimpse of when the outbreak might end as well as where we are with herd immunity, the MMR vaccine’s efficacy, and insights on breakthrough cases.

75% effectiveness of RSV vaccines in adults aged 60 and older, along with key safety considerations and broadened recommendations for high-risk groups.

Regulatory action follows reports of serious adverse events during use in elderly individuals; vaccine remains authorized for younger age groups in the US and Europe with over 40,000 doses administered globally.

Phase 3 data link gut microbiome shifts to better mental health outcomes in patients treated with fecal microbiota, live-jslm.

The company detailed its preliminary 24-week post–end-of-treatment data for its tobevibart and elebsiran combination, which is being studied for chronic hepatitis B.

A study of an H5N1 strain from a Michigan dairy worker showed airborne transmission in ferrets, bulevirtide achieved sustained virologic response in chronic hepatitis D patients, and more.

Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.

Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.

Vibrant Wellness’ Jason Barker, ND, outlines prevention measures, diagnostic red flags, and advances in multiplex testing for tick-borne diseases.

A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.

Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.

LA County confirms 165 cases since 2024 with 29 in 2025 alone, including individuals without known risk factors.